Dr. Nicole Verdun Shares How Patient Data Impacts CMC Robustness
When CGT products demonstrate dramatic improvements with minimal safety concerns in a Phase 2 study, Sponsors may want to modify the protocol mid-study to increase patient enrollment and convert it to a pivotal study. Here, Dr. Nicole explains how the Agency evaluates patient data from a clinical endpoint and CMC robustness perspective from patients enrolled before and after the change.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Thermo Fisher Scientific Bioproduction
This website uses cookies to ensure you get the best experience on our website. Learn more